HALOHalozyme Therapeutics Inc.
HALO
Halozyme Therapeutics Inc.4,927
Mkt Cap
$8.1BVolume
2.0052W High
$82.2252W Low
$47.50PE Ratio
27.45HALO Fundamentals
Price
$68.40Prev Close
$68.41Open
$68.8150D MA
$67.95Beta
0.73Avg. Volume
1.57MEPS (Annual)
$2.56P/B
165.04Rev/Employee
$3.3M$10,373.12
Boston Trust Walden Corp Sells 52,058 Shares of Halozyme Therapeutics, Inc. $HALO
Boston Trust Walden Corp reduced its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 6.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 781,835 shares of the biopharmaceutical company's stock after selling 52,058 s...
MarketBeat·1d ago
Choreo LLC Sells 28,448 Shares of Halozyme Therapeutics, Inc. $HALO
Choreo LLC reduced its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 90.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,075 shares of the biopharmaceutical company's st...
MarketBeat·1d ago
Assetmark Inc. Has $9.25 Million Position in Halozyme Therapeutics, Inc. $HALO
Assetmark Inc. increased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 11.9% in the 4th quarter, according to the company in its most recent 13F filing with the...
MarketBeat·5d ago
Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock?
Travere (TVTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks·8d ago
Paragon Capital Management Inc. Purchases New Shares in Halozyme Therapeutics, Inc. $HALO
Paragon Capital Management Inc. purchased a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 18,920 shares of the biopharmaceutical compan...
MarketBeat·10d ago
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Halozyme Therapeutics stock on March 9th. The tra...
MarketBeat·14d ago
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 10,000 Shares of Stock
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CEO Helen Torley sold 10,000 shares of the stock in a transaction on Monday, April 6th. The stock was sold at an average price of $63.50, for a total transaction of $635,000.00. Following the sale, the chief executive officer owned 767,780...
MarketBeat·15d ago
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of "Hold" by Brokerages
Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) have earned an average recommendation of "Hold" from the twelve analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have given a hold rec...
MarketBeat·15d ago
Helen Torley Sells 10,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) CEO Helen Torley sold 10,000 shares of the stock in a transaction dated Monday, April 6th. The stock was sold at an average price of...
MarketBeat·16d ago
Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon Technology
Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon Technology Halozyme Announces Global Collaboration and License Agreement with Vertex...
PR Newswire·16d ago
<
1
2
...
>